---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-016557"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:22:25.893829+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharma CEO Kaouthar Lbiati resigns; separation agreement provides $225K payment

## Summary
- Separation agreement pays Dr. Lbiati $225,000, $30,625 pro-rata bonus, and 6 months COBRA reimbursement.
- Lbiati resigned as CEO on March 16, 2026, and as director on April 13, 2026.
- Gary Stetz serves as Interim CEO effective from the separation date.
- Separation includes a general release and confidentiality covenant.

## SEC filing metadata
- accession: 0001493152-26-016557
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000149315226016557/0001493152-26-016557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000149315226016557/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-016557
- JSON: https://secwatch.observer/filing/0001493152-26-016557.json
- Plain text: https://secwatch.observer/filing/0001493152-26-016557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.